Business

Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in the Phase III Clinical Trial of BL-M05D1 for Injection (ADC) for Previously First-Line Treated Claudin18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in the Phase III Clinical Trial of BL-M05D1 for Injection (ADC) for Previously First-Line Treated Claudin18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AJune 4, 20263/news/announcement-on-voluntary-disclosure-of-the-completion-of-the-first-subject-enrollment-in-the-phase-iii-clinical-trial-of-bl-m05d1-for-injection-adc-for-previously-first-line-treated-claudin182-positive-advanced-gastric-cancer-or-gastroesophageal-junction-adenocarcinoma
Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in the Phase III Clinical Trial of BL-M05D1 for Injection (ADC) for Previously First-Line Treated Claudin18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in the Phase III Clinical Trial of BL-M05D1 for Injection (ADC) for Previously First-Line Treated Claudin18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A